OBJECTIVES: To describe the tolerance to long-term telavancin therapy among inpatients as it relates to nephrotoxicity. METHODS: Retrospective cohort study of adult patients who received telavancin at the Barnes-Jewish Hospital from 1 September 2009 to 1 December 2010. Patients who received less than three doses of telavancin, were on haemodialysis prior to telavancin administration or died within 48 h of initial telavancin administration were excluded. RESULTS: Twenty-one patients received telavancin and met the inclusion criteria. Seven of 21 patients (33%) developed acute renal insufficiency during therapy. Patients who developed acute renal insufficiency had a mean glomerular filtration rate reduction of 56 mL/min/1.73 m(2). In the univariate analysis, high body mass index (P=0.025), use of intravenous contrast dye (P=0.017) and prior serum vancomycin trough levels >20 mg/L (P=0.017) were associated with developing acute renal insufficiency. Two patients required haemodialysis; two had persistent renal insufficiency. CONCLUSIONS: Supratherapeutic vancomycin trough levels, high body mass index and receipt of intravenous contrast dye prior to telavancin therapy were associated with acute renal insufficiency.
OBJECTIVES: To describe the tolerance to long-term telavancin therapy among inpatients as it relates to nephrotoxicity. METHODS: Retrospective cohort study of adult patients who received telavancin at the Barnes-Jewish Hospital from 1 September 2009 to 1 December 2010. Patients who received less than three doses of telavancin, were on haemodialysis prior to telavancin administration or died within 48 h of initial telavancin administration were excluded. RESULTS: Twenty-one patients received telavancin and met the inclusion criteria. Seven of 21 patients (33%) developed acute renal insufficiency during therapy. Patients who developed acute renal insufficiency had a mean glomerular filtration rate reduction of 56 mL/min/1.73 m(2). In the univariate analysis, high body mass index (P=0.025), use of intravenous contrast dye (P=0.017) and prior serum vancomycin trough levels >20 mg/L (P=0.017) were associated with developing acute renal insufficiency. Two patients required haemodialysis; two had persistent renal insufficiency. CONCLUSIONS: Supratherapeutic vancomycin trough levels, high body mass index and receipt of intravenous contrast dye prior to telavancin therapy were associated with acute renal insufficiency.
Authors: Kristen L Bunnell; Manjunath P Pai; Monica Sikka; Susan C Bleasdale; Eric Wenzler; Larry H Danziger; Keith A Rodvold Journal: Antimicrob Agents Chemother Date: 2018-03-27 Impact factor: 5.191
Authors: Michael S Pulia; Mary R Calderone; John R Meister; Jamie Santistevan; Larissa May Journal: Curr Infect Dis Rep Date: 2014-09 Impact factor: 3.725
Authors: Fernando J Diggs; Jonathan D Edwards; Kimberly B Garza; Ali A M Hassoun; Spencer H Durham Journal: Antimicrob Agents Chemother Date: 2021-10-18 Impact factor: 5.938
Authors: Konstantinos A Polyzos; Michael N Mavros; Konstantinos Z Vardakas; Marinos C Makris; Petros I Rafailidis; Matthew E Falagas Journal: PLoS One Date: 2012-08-16 Impact factor: 3.240